Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20693641 | 1.00 | KDM4E (0.47) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL21057416 | 0.95 | KDM4E (0.52) | KDM4EL3MBTL1RAB9AALDH1A1ATM | |
| SCHEMBL10118460 | 0.89 | L3MBTL1 (0.46) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL21702576 | 0.87 | L3MBTL1 (0.61) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL14501994 | 0.87 | L3MBTL1 (0.61) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL8416943 | 0.87 | L3MBTL1 (0.61) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL12437188 | 0.86 | RAB9A (0.42) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL4744377 | 0.85 | KMT2A (0.46) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL14294016 | 0.85 | KMT2A (0.46) | KDM4EL3MBTL1POLBRAB9AALDH1A1 | |
| SCHEMBL14144107 | 0.85 | POLB (0.45) | KDM4EL3MBTL1POLBRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| EP-0320032-B1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-01-18 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| US-5106973-A | Viricide intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-21 | — | — | US | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
| EP-0320032-A1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885L3MBTL1 4307/4885POLB 1747/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885L3MBTL1 4307/4885POLB 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.